C&EN White Paper
Nitrosamines Analysis: Solutions for Risk Management and Analytical Testing from Experienced Industry Leaders
Brought to you by Cambrex
Overview

Given stringent regulatory guidelines regarding the presence of nitrosamines, drug innovators and manufacturers must consider control of these impurities not only in the active pharmaceutical ingredient (API) chemical process, but also in their starting materials, solvents, and more. A plan for control early in development is critical to maintaining product quality and safety. Partnering with the right CDMO can help mitigate risk throughout the process.

Key Objectives:
  • Definition/overview of nitrosamines
  • Risk assessment for the potential formation of nitrosamines
  • Development and validation of analytical methodology
  • Analytical considerations

Brought to you by:
This content was created by Cambrex, without editorial input from the C&EN Media Group. For more information on C&EN's custom products, visit our C&EN Media Kit.
Please complete the form to download the white paper.
* By submitting this form, you agree to receive more information on related products and services from the American Chemical Society and its sponsor via email. You understand that you can withdraw your consent at any time. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.

Copyright © 2024 American Chemical Society | 1155 Sixteenth Street NW | Washington, DC 20036 | View our Privacy Policy